Press Releases

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023

November 9, 2023

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

November 7, 2023

Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition

November 2, 2023

Poseida Therapeutics Announces Leadership Transition

October 9, 2023

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

September 5, 2023

Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

August 8, 2023

Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

August 7, 2023

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

August 7, 2023

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies

July 5, 2023